Cargando…

Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia

INTRODUCTION: Long-term adverse symptoms of men who used oral finasteride against androgenic alopecia have been recently described as post-finasteride syndrome (PFS). AIM: To determine whether (CAG)n-rs4045402 and (GGN)n-rs3138869 polymorphisms in the androgen receptor (AR) gene are implicated in PF...

Descripción completa

Detalles Bibliográficos
Autores principales: Cauci, Sabina, Chiriacò, Giovanni, Cecchin, Erika, Toffoli, Giuseppe, Xodo, Serena, Stinco, Giuseppe, Trombetta, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302381/
https://www.ncbi.nlm.nih.gov/pubmed/28024997
http://dx.doi.org/10.1016/j.esxm.2016.11.001
_version_ 1782506531409887232
author Cauci, Sabina
Chiriacò, Giovanni
Cecchin, Erika
Toffoli, Giuseppe
Xodo, Serena
Stinco, Giuseppe
Trombetta, Carlo
author_facet Cauci, Sabina
Chiriacò, Giovanni
Cecchin, Erika
Toffoli, Giuseppe
Xodo, Serena
Stinco, Giuseppe
Trombetta, Carlo
author_sort Cauci, Sabina
collection PubMed
description INTRODUCTION: Long-term adverse symptoms of men who used oral finasteride against androgenic alopecia have been recently described as post-finasteride syndrome (PFS). AIM: To determine whether (CAG)n-rs4045402 and (GGN)n-rs3138869 polymorphisms in the androgen receptor (AR) gene are implicated in PFS. METHODS: AR polymorphisms were studied according to PFS symptoms in 66 white participants (31.8% Italian, 28.8% American, and 39.4% other). MAIN OUTCOME MEASURES: Symptoms were investigated by an ad hoc 100-item questionnaire and the Arizona Sexual Experience Scale and Aging Male Symptom Scale (AMS). (CAG)n and (GGN)n repeats were categorized as short ([CAG]9–19, [GGN]<23), medium ([CAG]20–24, [GGN]23), or long ([CAG]25–37, [GGN]>23). RESULTS: Median age was 32 years, duration of finasteride use was 360 days, and time from finasteride discontinuation was 1,053 days. We observed several frequency differences in symptoms according to (CAG)n and (GGN)n repeat numbers. Three AMS items were worse for medium (GGN)23 than for long (GGN)>23 carriers and one item was worse for short (GGN)<23 carriers. The AMS item for decrease in sexual desire or libido was worse for short (CAG)9–19 carriers than for medium (CAG)20–24 carriers. Through the ad hoc questionnaire, significant findings in (CAG)n and/or (GGN)n repeats were obtained for penile discomfort, loss of scrotal sensitivity, scrotal discomfort, less pubic hair, loss of perceived perineal fullness, increased sperm density, involuntary muscle spasms, loss of muscle tone, increased weight (>2 kg), increased skin dryness, and onset of symptoms after finasteride use. CONCLUSION: This study showed that short and/or long (CAG)n and (GGN)n repeats had different frequencies according to symptoms reported by patients with PFS, likely reflecting the vast array of genes modulated by the AR. This study showed a U-curvilinear profile of (CAG)n repeats for skin dryness symptoms, where the two extremes exhibited a worse condition than medium repeats. Further studies are necessary to investigate the PFS pathophysiology using a precision medicine approach.
format Online
Article
Text
id pubmed-5302381
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-53023812017-02-17 Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia Cauci, Sabina Chiriacò, Giovanni Cecchin, Erika Toffoli, Giuseppe Xodo, Serena Stinco, Giuseppe Trombetta, Carlo Sex Med Original Research INTRODUCTION: Long-term adverse symptoms of men who used oral finasteride against androgenic alopecia have been recently described as post-finasteride syndrome (PFS). AIM: To determine whether (CAG)n-rs4045402 and (GGN)n-rs3138869 polymorphisms in the androgen receptor (AR) gene are implicated in PFS. METHODS: AR polymorphisms were studied according to PFS symptoms in 66 white participants (31.8% Italian, 28.8% American, and 39.4% other). MAIN OUTCOME MEASURES: Symptoms were investigated by an ad hoc 100-item questionnaire and the Arizona Sexual Experience Scale and Aging Male Symptom Scale (AMS). (CAG)n and (GGN)n repeats were categorized as short ([CAG]9–19, [GGN]<23), medium ([CAG]20–24, [GGN]23), or long ([CAG]25–37, [GGN]>23). RESULTS: Median age was 32 years, duration of finasteride use was 360 days, and time from finasteride discontinuation was 1,053 days. We observed several frequency differences in symptoms according to (CAG)n and (GGN)n repeat numbers. Three AMS items were worse for medium (GGN)23 than for long (GGN)>23 carriers and one item was worse for short (GGN)<23 carriers. The AMS item for decrease in sexual desire or libido was worse for short (CAG)9–19 carriers than for medium (CAG)20–24 carriers. Through the ad hoc questionnaire, significant findings in (CAG)n and/or (GGN)n repeats were obtained for penile discomfort, loss of scrotal sensitivity, scrotal discomfort, less pubic hair, loss of perceived perineal fullness, increased sperm density, involuntary muscle spasms, loss of muscle tone, increased weight (>2 kg), increased skin dryness, and onset of symptoms after finasteride use. CONCLUSION: This study showed that short and/or long (CAG)n and (GGN)n repeats had different frequencies according to symptoms reported by patients with PFS, likely reflecting the vast array of genes modulated by the AR. This study showed a U-curvilinear profile of (CAG)n repeats for skin dryness symptoms, where the two extremes exhibited a worse condition than medium repeats. Further studies are necessary to investigate the PFS pathophysiology using a precision medicine approach. Elsevier 2016-12-23 /pmc/articles/PMC5302381/ /pubmed/28024997 http://dx.doi.org/10.1016/j.esxm.2016.11.001 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Cauci, Sabina
Chiriacò, Giovanni
Cecchin, Erika
Toffoli, Giuseppe
Xodo, Serena
Stinco, Giuseppe
Trombetta, Carlo
Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia
title Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia
title_full Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia
title_fullStr Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia
title_full_unstemmed Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia
title_short Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia
title_sort androgen receptor (ar) gene (cag)n and (ggn)n length polymorphisms and symptoms in young males with long-lasting adverse effects after finasteride use against androgenic alopecia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302381/
https://www.ncbi.nlm.nih.gov/pubmed/28024997
http://dx.doi.org/10.1016/j.esxm.2016.11.001
work_keys_str_mv AT caucisabina androgenreceptorargenecagnandggnnlengthpolymorphismsandsymptomsinyoungmaleswithlonglastingadverseeffectsafterfinasterideuseagainstandrogenicalopecia
AT chiriacogiovanni androgenreceptorargenecagnandggnnlengthpolymorphismsandsymptomsinyoungmaleswithlonglastingadverseeffectsafterfinasterideuseagainstandrogenicalopecia
AT cecchinerika androgenreceptorargenecagnandggnnlengthpolymorphismsandsymptomsinyoungmaleswithlonglastingadverseeffectsafterfinasterideuseagainstandrogenicalopecia
AT toffoligiuseppe androgenreceptorargenecagnandggnnlengthpolymorphismsandsymptomsinyoungmaleswithlonglastingadverseeffectsafterfinasterideuseagainstandrogenicalopecia
AT xodoserena androgenreceptorargenecagnandggnnlengthpolymorphismsandsymptomsinyoungmaleswithlonglastingadverseeffectsafterfinasterideuseagainstandrogenicalopecia
AT stincogiuseppe androgenreceptorargenecagnandggnnlengthpolymorphismsandsymptomsinyoungmaleswithlonglastingadverseeffectsafterfinasterideuseagainstandrogenicalopecia
AT trombettacarlo androgenreceptorargenecagnandggnnlengthpolymorphismsandsymptomsinyoungmaleswithlonglastingadverseeffectsafterfinasterideuseagainstandrogenicalopecia